CAR Stock Recent News
CAR LATEST HEADLINES
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Avis Budget Group, Inc ("Avis Budget" or the "Company") (NASDAQ:CAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Avis Budget Group, Inc ("Avis Budget" or the "Company") (NASDAQ:CAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Avis Budget Group, Inc ("Avis Budget" or the "Company") (NASDAQ:CAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK , March 4, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Avis Budget Group, Inc. ("ABG") (NASDAQ: CAR). The investigation concerns whether Avis Budget Group, Inc. and certain of its officers and/or directors have engaged in securities fraud.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avis Budget Group, Inc ("Avis Budget" or the "Company") (NASDAQ: CAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHANGHAI , March 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to satricabtagene autoleucel ("satri-cel", CT041) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction cancer (G/GEJ) in patients who have failed at least two prior lines of therapy. The company plans to submit a New Drug Application (NDA) for satri-cel to the NMPA in the first half of 2025.
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Avis Budget Group, Inc. ("Avis Budget" or "the Company") (NASDAQ:CAR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Avis Budget Group, Inc. ("Avis Budget" or "the Company") (NASDAQ:CAR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.